In Line Aerosol Nebulization With High Flow

Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · May 25, 2023

Keywords

ClinConnect Summary

**Clinical Trial Summary: In Line Aerosol Nebulization With High Flow**

This clinical trial, called ILAN, is exploring a new way to deliver medication to patients experiencing breathing difficulties, specifically those with hypoxemic respiratory failure and airway obstruction. The main goal is to compare a method that uses high-flow nasal cannula (HFNC) with a special nebulizer against the traditional way of using a jet nebulizer with a mask. Researchers believe that the new method might be safer and easier for patients while still delivering the same benefits of medication to help open up the airways.

To participate in this trial, you need to be an adult aged 18 or older who has been diagnosed with mild to moderate breathing difficulties and is receiving treatment with HFNC. You should also have been prescribed nebulized medications like albuterol or ipratropium. If you’re interested in joining, you can expect to receive either the new nebulization method or the standard treatment while being monitored by the medical team. This trial is actively recruiting participants, and it’s important to note that some individuals, such as those with severe breathing issues or certain health conditions, may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults ≥ 18 years of age
• • Patients with mild or moderate hypoxemic respiratory failure (with or without acute hypercapnic respiratory failure) treated with HFNC.
• • Nebulizer therapy ordered by the primary team with at least one dose delivered prior to the enrollment into the study
• • Patients must be on ordered nebulized albuterol, levalbuterol, ipratropium or ipratropium/albuterol combination with a maximum of Q3 or a minimum of Q6 hour frequencies.
• • For Respiratory Therapists: They must be employees of SMICU or RRMC.
• Exclusion Criteria:
• • Lack of hypoxemia defined as SpO2\> 92% on room air
• • Severe hypoxemia defined by PaO2/FiO2\<100 or SpO2\<92% on HFNC settings: ≥ FiO2 80% or higher and O2 flow 40L/min
• • HFNC O2 delivery via tracheostomy
• • COVID-19 positive status (within 3 weeks prior to the enrollment)
• • Respiratory distress, defined by respiratory rate \> 24 breath per minute
• • Hemodynamic instability defined by the use of two or more vasopressor medications
• • Presence of nasal obstruction that may pose a risk for inadequate nebulizer delivery in the opinion of the investigator
• • Pulmonary comorbidities that, in the opinion of the investigator or clinical team, can pose a risk to subject safety or interfere with the subject's ability to complete the study procedures.
• • Moribund patient not expected to survive \>24 hours
• • Inability to obtain informed consent from patient
• • Respiratory therapists who are unwilling to participate.